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Summary.-The effect of transplanted syngeneic methylcholanthrene induced
fibrosarcomata on the primary immune response of CBA and A/HeJ mice to
standard doses of alum BSA, SRBC and SIII has been investigated. In animals
with established fibrosarcomata the responses were (with one exception) either
normal or elevated. Cell transfer studies in sublethally irradiated syngeneic re-
cipients confirmed that the spleens froim tumour bearing mice were capable of
responding effectively to all 3 antigens. In animals simultaneously challenged with
viable sarcoma cells and antigen the response to alum BSA was suppressed while
those to SRBC and SIII were often enhanced. Furthermore the secondary response
of A/HeJ mice to BSA was also suppressed by the simultaneous injection of viable
fibrosarcoma cells. The administration of C. parvum 3 days after antigen had a
variable effect. Nevertheless in a number of cases it significantly increased the
primary response to all 3 antigens. It also inhibited the growth of the CBA fibro-
sarcoma but was without effect on the A/HeJ fibrosarcoma.
DURING the past decade there have
been numerous investigations oIn the
immune responsiveness of patients and
animals with tumours of the lymphoreti-
cular system or of other tissues. In
general these studies indicate that there
is an impairment of cell mediated immu-
nity in many tumour bearing subjects
including those witlh non-lymphomatous
cancers. In contrast, the effect on hu-
moral immunity is believed to be less
marked (for example, see Miller, 1968;
Southam, 1968).
As a result of recent advances in our
understanding of huimoral immune re-
sponses and the current interest in the
use of adjuvants in tumour therapy, we
felt it was necessary to determine the
effect of established and simultaneously
transplanted tumour on the humoral
response to thymus dependent and inde-
pendent antigens and to ascertain if this
response could be modified by a Coryne-
bacterium parvum (C. parvum) protocol
which has previously been shown to
inhibit tumour growth (Woodruff, Inchley
and Duinbar, 1972). We have therefore
studied the effect of transplanted syn-
geneic methylcholanthrene induced fibro-
sarcomata (MC fibrosarcomata) and this
C. parvetn schedule on the primary im-
mune response of CBA and A/HeJ mice
to bovine serum albumin (a thymus
dependent antigen, Taylor, 1969), sheep
erythrocytes (an essentially thymus de-
pendent antigen, Playfair and Purves,
1971) and type III pneumococcus poly-
saccharide (a thymus independent antigen,
Davies et al., 1970; Howard et al., 1971).
As a further test of the immunocom-
petence of spleen cells from tumour
bearing animals, we have also assessed
their ability to restore the response of
sublethally irradiated syngeneic recipientsK. JAMES, A. GHAPPAR AND I. MILNE
to thymus dependent and independent
antigens.
MATERIALS AND METHODS
Mice.-The experiments were performed
in inbred adult (approximately 3-month old)
male CBA/H or A/HeJ mice. The A/HeJ
mice were bred by brother-sister mating
from mice obtained from the Jackson
Memorial Laboratories, Bar Harbor, Maine,
U.S.A., while the CBA mice were bred from
mice purchased from the M.R.C. Laboratory
Animals Centre, Carshalton, Surrey.
Tumours.-The fibrosarcomata used were
originally induced in 8-10 week old CBA
and A/HeJ mice by a single intramuscular
injection of 0 5 mg methylcholanthrene in
0 1 ml of trioctanoin. The tumours were
propagated routinely by subcutaneous (s.c.)
transplantation of a small piece of tissue.
However, in the experiments to be described,
transplantation was performed by the sub-
cutaneous injection into the right thigh of a
viable suspension prepared with pronase as
previously described by Woodruff and Boak
(1966). The CBA and A/HeJ fibrosarcomata
had been transplanted 15 and 19-22 times
respectively before experimentation. The
tumour growths (expressed as mean diameter
in mm) were continuously assessed through-
out the period of experimentation.
Corynebacterium parvum.-This was a
formalin killed suspension (Batch No. WEZ
174) kindly provided by Dr Griffiths of the
Wellcome Research Laboratories, Langley
Court, Beckenham, Kent. The suspension
(containing 1-4 mg dry weight of organism)
was routinely administered intraperitoneally
(i.p.) 3 days following tumour transplanta-
tion. As previously indicated, this protocol
has been shown to delay the growth of MC
fibrosarcomata in CBA and A/HeJ mice
(Woodruff et al., 1972).
Antigenic challenge and assessment of
immune response.-Details of the preparation
of the alum precipitated bovine serum
albumin (alum BSA) are recorded elsewhere
(James and Milne, 1972). The mice were
challenged i.p. with 0.2 ml of inoculum
containing 1 mg of the protein and bled at
selected time intervals thereafter. The anti-
gen binding capacity (ABC) and relative
binding affinity (RBA) of the sera were
determined by the Farr procedure as pre-
viously described (Farr, 1958; James and
Milne, 1972).
The sheep erythrocytes (3 x 108 SRBC)
were injected i.p. and 6 or 8 days later the
direct and indirect plaque forming cell
(PFC) response of individual spleens was
determined by a modification of the Jerne
plaque cell technique (Ghaffar and James,
1973a).
The purified type III pneumococcus
polysaccharide antigen (SIII) was kindly
supplied by Dr J. G. Howard of the Well-
come Research Laboratories, Beckenham,
Kent. This was administered i.p. in 1 jug
doses and the immune response elicited in
individual spleens was again determined by
the PFC technique 5 or 7 days following
antigen challenge (Ghaffar and James,
1973b).
Presentation of results.-The ABC, PFC
and tumour diameter data are all expressed
as geometric mean values, together with
the limits of one standard error from the
mean. The RBA data are expressed as
arithmetic means ± one standard error.
Furthermore as the tumours and C. parvum
sometimes caused splenomegaly, the PFC
content per 106 nucleated spleen cells and
per spleen have both been presented. The
significance of all the results (P values)
have been determined by the standard
2 tail " t " test method. It should also
be noted that the immune response to
SRBC was also routinely assessed by standard
serological procedures (Ghaffar and James,
1973a) but as these results were in close
agreement with the PFC data they have
been omitted in order to simplify presenta-
tion.
RESULTS
The effect of transplanted fibrosarcoma cells
and C. parvu.m on primary humoral
responses
In these experiments haif the animals
were challenged with i.p. injection of
standard doses of one of the test antigens
and at the same time they received a
s.c. injection of 1 x 104 or 1 x 105 viable
MC fibrosarcoma cells (see Tables I and
II). The normal mouse controls were
injected with antigen alone. Three days
later halfthe mice in both the normal and
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TABLE I.-The Primary Immune Response to Thymus Dependent and Independent
Antigens in CBA Mice Simultaneously Challenged with Viable Methylcholanthrene
Induced Fibrosarcoma Cells* and Subsequently Treated with Corynebacterium
parvum
C.
parvum
No
Yesf
No
Yesf
No
Yes
No
Yes
Assay
Antigen binding
capacity
Relative binding
affinity
fDirect PFC/106
Direct PFC/spleen
fDirect PFC/106
Direct PFC/spleen
rIndirect PFC/106
Indirect PFC/spleen
Indirect PFC/s106
Indirect PFC/spleen
SiII No fDirect PFC/106
(1.0 Esg) IDirect PFC/spleen
Yes Direct PFC/106
Direct PFC/spleen
Normal mice controlst
(mean±s.e.)
9 20 (8 82-9 60)
13.22 (11-1-15-75)
52 - 5 (47 -1-56- 9)
45-8 (41-9-49-6)
20-8 (18-24)
3223 (2856-3637)
18-2 (15-6-21-3)
5148 (4293-6175)
323 (254-412)
50,536 (37,325-68,420)
319 (258-396)
90,157 (69,400-117,120)
16-8 (12-23-5)
1986 (1414-2789)
20 (15-8-25-5)
3135 (2365-4154)
Mice challenged with
tumour
(mean+s.e.)
5-75 (5-17-6-39)
6-48 (5.30-7 92)
50 4 (46 2-54. 6)
61-8 (56 2-67.3)
17-8 (15-5-20-5)
2523 (2236-2847)
19-8 (16-4-23-8)
5046 (3170-6106)
286 (239-343)
39,828 (33,799-46,933)
381 (344-422)
97,224 (88,055-107,348)
19 (9-24)
2087 (1278-3409)
37-3 (30.4-45.8)
7161 (5615-9133)
* Animals injected with BSA received 1 x 104 viable cells, the others 1 x 105.
t Each group contained 4-8 mice.
t Inall tablesP refers to significance between tumour bearing or tumour challenged mice and " normal "
cantrols.
TABLE II.-The Primary Immune Response to Thymus Dependent and Independent
Antigens in A/HeJ Mice Simultaneously Challenged with Viable Methylcholanthrene
Induced Fibrosarcoma Cells* and Subsequently Challenged with Corynebacterium
parvum
Antigen
BSA
(1 mg in
alum)
SRBC
(3 x 108)
C.
parvum Assay
No \ Antigen binding
Yes f capacity
No l Relative binding
Yes affinity
No Direct PFC/106
° Direct PFC/spleen
Yes fDirect PFC/106
Direct PFC/spleen
No Indirect PFC/106 Indirect PFC/spleen
Yes Indirect PFC/106
Indirect PFC/spleen
SIII fDirect PFC/106
(1-0 ,g) No Direct PFC/spleen
Yes Direct PFC/106 Direct PFC/spleen
* Animals injected with BSA received
t Each group contained 6-10 mice.
Normal mice controlst
(mean ± s.e.)
10-90 (9-82-12- 11)
17- 99 (15- 05-21- 51)
50 3 (46.0-54 6)
43-7 (40.7-46.7)
23-3 (19-3-28-2)
6757 (5841-7818)
14 (11.5-17)
5231 (4812-5542)
133-4 (120-3-145)
38,625 (36,456-40,924)
92 (73-6-115-6)
38,548 (26,813-44,513)
1-(0) (0-8-1-4)
200 (145-275)
2 - (1) (1- 6-2 - 8)
639 (490-832)
Mice challenged with
tumour
(mean ± s.e.)
4-12 (3-61-4-70)
14-55 (12-66-16- 72)
50- 5 (45.6-55.4)
59- 8 (54.9-64.7)
26- 2 (25-1-27-4)
7012 (6173-7965)
17-4 (14-7-20-7)
6936 (6060-7939)
127-4 (117-139)
37,193 (35,762-38,681)
149 (128-174)
59,332 (49,472-71,157)
4-1 (3-1-5-4)
721 (536-970)
2-8 (2-1-3-8)
658 (480-901)
1 x 104 viable cells, the others 1 x 105.
Antigen
BSA
(1 mg in
alum)
SRBC
(3 x 108)
Significancel
p
0-001
0-02
0 7
0-025
0 4-0 5
0-1-0-2
0-7-0-8
0 9-0 95
0 7
0 4-0 5
0-4-0 5
0-6-D-7
0 8-0 9
0*9-095
0-05-0 1
0-05-0-1
Signifi-
cance
p
<0-001
0 3-0-4
0 975
0 005
0-5-0-6
0-8-0-9
0 4
0 3
0 7-0 9
0-6
0-1
0-1-0-2
=0 005
0-02
-0.5
=0 95K. JAMES, A. GHAFFAR AND I. MILNE
tumour groups were injected i.p. with
1-4 mg C. parvum. The circulating anti-
body response to BSA was determined
21 days after challenge, while the splenic
PFC response to Sill and SRBC were
assessed 7 and 8 days respectively follow-
ing antigen challenge. The results of
these experiments are summarized in
Tables I and II.
It will be observed that the simul-
taneous administration of 1 x 104 viable
tumour cells along with alum BSA
significantly suppressed the quantity of
antibody elicited by this antigen (i.e.
suppressed the ABC values). The ad-
ministration of tumour cells, however,
had no effect on the quality of the anti-
bodies produced (RBA). Subsequent
treatment with C. parvum potentiated
the overall immune response to alum
BSA in normal CBA mice but had no
significant effect in tumour bearing ani-
mals (Table I). In contrast, it poten-
tiated the immune response of both
normal and tumour challenged A/HeJ
mice (Table II). The C. parvum protocol
used also significantly increased the rela-
tive binding affinity of antibody produced
in tumour bearing animals.
On no occasion did the simultaneous
administration of viable MC fibrosarcoma
cells suppress the splenic PFC response
to SRBC or SIII. In contrast, on one
occasion the tumour cells appeared to
potentiate the splenic PFC response
(namely the response of A/HeJ mice to
SIII-Table II).
The effect of the C. parvum therapy
upon the response of normal and tumour
bearing mice to SRBC was variable.
On 3 out of 4 occasions it significantly
increased the number of direct and in-
direct PFC per spleen in CBA mice. It
shouid be noted that PFC per 106 nucleat-
ed spleen cells were enhanced only on a
few occasions. In contrast, the PFC
response per spleen was potentiated only
on one occasion in A/HeJ mice (Table
III).
C. parvum treatment caused a definite
increase in the anti-Slll response of both
A/HeJ and CBA mice challenged with
TABLE III.-The Primary Immune Response to Thymus Dependent and Independent
Antigens in CBA Mice with Established Transplanted Methylcholanthrene Induced
Fibrosarcormata*
Dayt
injected
8
Tumour
size:
(mm)
6-2
(5.9-6.6)
14 11-4
(10-2-12-7)
14 13* )
(12- 1-14-0)
Assay
Antigen binding
capacity
Relative binding
affinity
Direct PFC/106
Direct PFC/spleen
Indirect PFC/106
Indirect PFC/spleen
Direct PFC/106
Direct PFC/spleen
Day of
assayt
23
20
Normal mice
controls§
(mean±s.e.)
2-75
(2.58-2.93)
29-1
(27.8-30.4)
77
(68 3-87)
9529
(8605-10,553)
343
(312-378)
42,442
(38,538-46,743)
19 9-8
(8-3-11.6)
1527
(1279-1825)
Tumour bearing
mice
(mean±s.e.)
2-12
(1-93-2.33)
28-6
(25.2-31.9)
71
(58-87 4)
15,466
(12,089-19,755)
339
(291-396)
74,064
(60,805-90,217)
13-8
(10-5-18-2)
2901
(2194-3824)
* 1 x 105 viable cells (s.c.) into right thigh.
t Day of tumour cell injection being Day 0.
t Mean tumour diameter (± s.e.) on day of antigen challenge.
§ Each group contained 9-10 mice.
Antigen
BSA
(1 mg in
alum)
SRBC
(3 x 108)
s1Ig
(1 yg)
Signifi-
cance
p
0 025
0-8-0*9
0-7-0-8
0-10
0.95
0 025
0 30
0 05
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tumour. However, it didnot significantly
affect this response in non-tumour bearing
mice.
The effect of the C. parvum therapy
on tumour growth also varied from
strain to strain. In CBA mice the
growth of the transplanted fibrosarcoma
cells was significantly inhibitedthroughout
the period of observation. The mean
tumour diameter (together with the limits
of one standard error from the mean) in
C. parvum treated mice were 3'0 (1.2-5.3)
and 17-0 (16-6-17-4) on Days 14 and 28
respectively. In animals not receiving C.
parvum the corresponding diameters were
7*4 (7-0-7-8) and 20-4 (19.3-21.3). In
contrast, C. parvum treatment had little
effect on tumour growth in A/HeJ mice,
the tumour diameters in the C. parvum
treated animals being 12-6 (12-3-13-0)
and 19-7 (19.0-20.4) on Days 14 and 28
respectively, while those in the non-
parvum group were 13*4 (12.6-14-1) and
21*6 (21-0-22-2).
The effects of established fibrosarcomata on
primary humoral responses
In order to determine the effect of
established fibrosarcomata on the primary
response to thymus dependent and inde-
pendent antigens the following experi-
ments were performed. Mice were in-
jected s.c. with 1 x 105 viable fibro-
sarcoma cells on Day 0 and on Day 8
or 14, when the tumour was established,
they were challenged with standard doses
of the test antigens (see Tables III and
IV). Antibodies to BSA were assayed
11-15 days following antigenic challenge
while the splenic PFC responses to SIII
and SRBC were determined 5 and 6
days respectively after challenge with
these antigens.
With one exception (see CBA mice
challenged with alum BSA-Table III)
the presence of established tumour failed
to suppress the primary immune response.
Indeed, on occasions the primary response
to SRBC and SIII was significantly
TABLE IV.-The Primary Immune Response to Thymus Dependent and Independent
Antigens in A/HeJ Mice with Established Transplanted Methylcholanthrene Induced
Fibrosarcomata
Dayt Tumour Day
in- sizet of Normal mice Tumour bearing Significance
Antigen iected (mm) Assay assayt controls mice P
BSA 8 6-7§ Antigen binding 23 5-46 4-46 0-4
(1 mg in (6-4-6-9) capacity (4-51-6-61) (3.99-4-98)
I "fl A Ol -'I A-aA-"~~~~~~61~ Relative binding
affinity
14 20 211 Antigen binding
(19-2-21.3) capacity
Relative binding
affinity
14 7- 3 Direct PFC/106
Direct PFC/spleen
Indirect PFC/106
Indirect PFC/
spleen
Direct PFC/106
Direct PFC/spleen
14 7-7
(7-4-7-9)
29- 0 31.1
(25.3-32-7) (29-2-33.1)
25 2-38 2-84
(2.03-2.80) (2-19-3-69)¶
Not determined
19 45-8
(37-56. 7)
11,816
(9477-14,733)
87
(61-4-123-7)
22,492
(15,649-32,326)
20 3-2
(2.4-444)
725
(545-965)
79.4
(69.6-90.6)
24,703
(20,734-29,433)
367
(297-455)
110,519
(86,916-140,531)
3-4
(2 5-4 5)
849
(639-1126)
U - j-7
0 5
005
0-01-0*02
0.005-0 001
0-005-0*001
-0 9
0 70
* 1 x 105 viable cells (s.c.) into right thigh.
t Day of tumour cell injection being Day 0.
I Mean tumour diameter (± s.e.) on day of Ag challenge except for § and 1 where the values are those
observed 12 and 19 days respectively following tumour challenge.
This group contained only 4 animals, all other groups contained 8-10.
2
alum)
(7 - 1-7 5)
SRBC
(3 x 108)
SIII
(1 mg)
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potentiated in animals with pre-existing
tumour, though this effect appeared to
vary from strain to strain. For example,
the response to SRBC was significantly
increased in A/HeJ mice (Table IV)
bearing tumours while the effect in CBA
(Table III) mice was marginal. In con-
trast, the response to Sll was signifi-
cantly enhanced in CBA (Table III) mice
bearing tumours but not in A/HeJ mice
(Table IV).
An examination of the growth of the
established tumours in CBA mice treated
with various antigens indicated that this
growth was much slower in mice chal-
lenged with alum BSA than in other
groups. For example, on Day 19 after
tumour injection the tumour diameter in
the alum BSA groups was 9-5 (84-108)
while in the mice receiving SRBC and
SIII the diameters were 13-5 (11-7-15.6)
and 16-6 (14-9-18.5) respectively. In
contrast, the growth of the established
tumours in A/HeJ mice was similar in all
groups.
The ability of spleen cells from tumour
bearing animals to restore humoral respon-
siveness to irradiated syngeneic recipients
As a further measure of the immuno-
logical capacity of tumour bearing mice,
lymphoid cells from A/HeJ mice challeng-
ed with 1 X 105 tumour cells 14 days
previously were transferred into normal
syngeneic animals. Following 600 rad
whole body x-irradiation recipient mice
were injected i.v. with 3-5 x 107 viable
nucleated spleen cells from either tumour
bearing or normal donors. Two to 3
days after repopulation the animals were
challenged i.p. with the standard doses
of the 3 test antigens. Circulating anti-
bodies to BSA were measured 18 days
following challenge with this antigen
while splenic PFC's were measured 5 and
6 days respectively following challenge
with SIII and SRBC.
From the results summarized in Table
V it can be seen that the response in
mice repopulated with spleen cells from
tumour bearing animals was almost iden-
tical to that observed in mice repopulated
with spleen cells from normal animals.
The effect of transplanted fibrosarcoma
cells and C. parvum on secondary humoral
responses
A/HeJ mice were sensitized on Day 0
by the i.p. injection of 1 mg of alum BSA.
On Day 21 halfthe mice were injected s.c.
with 1 x 105 viable fibrosarcoma cells
(the tumour challenged group) and 0.1 mg
of soluble BSA (i.p.). The remainder
(which served as controls) were challenged
TABLE V.-The Ability of Sublethally X-irradiated (600 rad) A/HeJ Mice to Respond
to Thymus Dependent and Independent Antigens Following Repopulation with
Spleen Cells* from Normal and Tumour Bearing Mice
X-irradiated micet repopulated with
syngeneic spleen cells from
Normal mice Tumour bearing mice Significance
Antigen Assay (mean + s.e.) (mean + s.e.) P
BSA Antigen binding 2 30 (1- 73-3 - 06) 2 - 33 (1 -93-2-82) 0-95
1 mg in alum) capacity
SRBC Direct PFC/106
(3 x 108) Direct PFC/spleen
Indirect PFC/106
Indirect PFC/spleen
SIII
(1 /g)
Direct PFC/106
Direct PFC/Spleen
4-4 (3 9-4 9)
817 (723-923)
8-7 (4-8-15-8)
1616 (869-3206)
21-3 (17-27)
3464 (2643-4541)
5 (4- 4-5 7)
862 (727-1022)
8- 6 (5-0-14- 8)
1464 (789-2717)
18- 6 (13 5-3647)
2624 (1892-3641)
* Animals injected i.v. with 3-5 x 107 viable spleen cells following x-irradiation and challenged with
antigen 2-3 days later.
t Each group contained 4-10 mice.
0-4
0-8
0-98
0 95
0-7-0-8
0 3
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TABLE VI.-The Secondary Immune Response to Alum BSA* in A/HeJ Mice Simul-
taneously Challenged with Methylcholanthrene Induced Fibrosarcoma Cells and
Subsequently Treated with C. parvum
C. parvum Assayt
No Antigen binding capacity
Relative binding affinity
Yes Antigen binding capacity
Relative binding affinity
Normal mice
controls$
(mean ± s.e.)
35-95
(32 8-39 4)
68-5
(63.1-73.9)
33 31
(29.52-37.59)
73.9
(69.0-78.7)
Mice challenged
with tumour
(mean ± s.e.)
26 31
(23.84-29.03)
59-3 (55.2-63.4)
18-66
(16 88-20 63)
67-5
(63.2-71.9)
* Mice injected i.p. with 1 mg of alum BSA on Day 0 and challenged i.p. on Day 21 with 100 ug of
soluble BSA with or without 1 x 105 viable tumour cells s.c. C. parvum was administered on Day 24.
t The antibody assays were performed on Day 41, that is 20 days after secondary challenge.
$ Each group contained 9-10 mice.
with antigen alone. Three days later
(Day 24) half of the normal controls and
half of the tumour challenged mice were
injected i.p. with 1-4 mg of formalized C.
parvum. On Day 41 antibody assays
were performed on all the mice and the
results obtained are summarized in Table
VI.
It will be observed that the secondary
ABC response in animals simultaneously
injected with tumour cells is significantly
lower than that in normal controls. In
contrast, however, the tumour inoculation
had no significant effect on the affinity of
the antibodies produced. Furthermore,
the C. parvum protocol used had no
significant effect on secondary humoral
immunity in tumour bearing or normal
animals. In addition, it failed to inhibit
the growth of the tumours significantly,
the tumour diameter in C. parvum treated
animals 17 days after transplantation
being 10-4 (9-.611.3) while that in un-
treated animals was 12-9 (11-8-14.2).
DISCUSSION
From the results presented it can be
concluded that in general there is no
significant suppression of the primary
humoral immune response to thymus
dependent and independent antigens in
CBA and A/HeJ mice with established
transplanted MC fibrosarcomata. In con-
trast, the primary and secondary immune
responses to alum BSA may be suppressed
ifviable fibrosarcoma cells are administer-
ed at the same time as the antigen.
These results are in agreement with
previous observations in animals (Mackay,
1964) and humans (Southam, 1968) with
non-lymphomatous tumours. They con-
trast, however, with other observations
in tumour bearing anim4ls (Kamo and
Ishida, 1971) and patients (Litton, Hughes
and Fulthorpe, 1964; Lee, Rowley and
Mackay, 1970). It is thus apparent that
theeffect oftumours onhumoralimmunity
is a variable one and difficult to predict
with any certainty.
Of particular interest in the present
studies were the observations that pre-
existing tumour might potentiate the
immune response to SRBC and SIII.
A similar increase in the response to
SRBC in sarcoma bearing rats (Alexander
et al., 1969) and to SIII antigen and
diphtheria toxoid in a limited number
of cancer patients (Leskowitz et al., 1957)
has been reported previously. It is ap-
preciated that the increased splenic PFC
responses reported in the present study
are in many cases due largely to the
splenomegaly associated with tumour
growth.
The observations that C. parvum may
potentiate the immune response of both
Significance
p
0-025-0-05
0-2
0-025
>0 9
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normal and tumour bearing mice to
thymus dependent and independent anti-
gens have previously been noted by
others in normal animals (Pinckard, Weir
and McBride, 1967; Howard, Christie and
Scott, 1973). In the present studies the
enhanced responses observed were prob-
ably due largely to the splenomegaly
associated with C. parvrum treatment. It
should be noted, however, that it has
been claimed that C. parvum may sup-
press the response to SIII if administered
at the same time as this antigen (Howard
et al., 1973).
The ability of C. parvum to delay the
growth of transplanted MC induced fibro-
sarcomata in CBA mice and other murine
tumours has been reported elsewhere
(Woodruff et al., 1972; Woodruff and
Dunbar, 1973; Woodruff and Boak, 1966;
Halpern et al., 1966; Smith and Scott,
1973). Moreover, recent studies indicate
that C. parvrum can exert this effect in
T deprived mice, suggesting that its anti-
tumour effect depends primarily on macro-
phage stimulation (Woodruff, Dunbar
and Ghaffar, 1973). The failure of C.
parvum to delay the growth of MC fibro-
sarcomata in A/HeJ mice contrasts with
the previous observations from this labora-
tory (Woodruff et al., 1972). It should
be noted, however, that the experimental
models used in these experiments were
different from those employed by the
above authors in that an additional
adjuvant was used in the present experi-
ments. Of further interest are the ob-
servations that alum BSA injections
significantly inhibited the growth of
established fibrosarcomata in CBA mice,
but not in A/HeJ mice. This was
probably due to the nonspecific stimula-
tion of the reticuloendothelial system by
the alum.
In Table VII the overall effect of our
C. parvum protocol on humoral immunity
in tumour bearing animals has been
summarized. This suggests that the C.
parvumn is more effective at potentiating
19s (IgM) responses in CBA mice with
fibrosarcomata than in A/HeJ mice with
similar tumours. It is possible therefore
that its superior tumour inhibiting poten-
tial in the CBA mice was due partly to
its capacity to elicit antitumour anti-
bodies of the IgM class, for these are
generally held to be more effective at
lysing target cells than their 7s (IgG)
counterparts. Conversely the ineffective-
ness of the C. parvum protocol in A/HeJ
mice may be due to its inability to
influence significantly the levels of cyto-
toxic IgM antibodies in this strain, or
alternatively because it favoured the
production of blocking antibodies.
At the present time we have no satis-
TABLE VII.-A Summary of the Effect of the Corynebacterium parvum Protocol on
the Huanoral Immune Response in Mice Simultaneously Transplanted with Viable
Fibrosarcoma Cells
Mouse
strain
CBA
Antigen
Alum BSA
SRBC
SIII
Tumour
A/HeJ Alum BSA
SRBC
SIII
Tumour
Assay
ABC
Direct PFC
Indirect PFC
Direct PFC
Growth
ABC
f Direct PFC
IIndirect PFC
Direct PFC
Growth
Effect
No effect
Significant potentiation
Significant potentiation
Significant potentiation
Significant inhibition
Significant potentiation
No significant effect
Significant potentiation
No significant effect
No significant effect
Note: In tumour bearing CBA mice the C. parvum potentiated the formation of IgM antibody but
failed to do so in A/HeJ mice.
Main
antibody
class
IgG
IgM
IgG
IgMI
IgG
IgM
IgG
IgM
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factory explanation of the differing effects
of established fibrosarcomata and of
simultaneously administered viable
tumour cells on the immune response to
alum BSA and the other antigens under
test. It is possible that during the initial
growth phase of the tumour there is a
tumour dependent depression of T cell
function. As a result the immune res-
ponse to antigens such as BSA, with a
high degree ofthymus dependency, maybe
suppressed. On the other hand, the res-
ponse to antigens such as SRBC (which
are less dependent upon T cell helper
function), and SIII (which does not re-
quire a T cell helper effect) are not signifi-
cantly affected. Later, when the tumour
has become established, there is a recovery
in T cell function enabling the animals
to mount a normal response to alum BSA.
In this connection it is interesting to note
that a humoral factor which depresses cell
mediated immunity has recently been
reported in patients with primary intra-
cranial tumours (Brooks et al., 1972).
While the present studies clearly
indicate that the overall immune response
to fixed doses of thymus dependent and
independent antigens is not affected by
established MC fibrosarcomata in CBA
and A/HeJ mice, they are of themselves
limited. It is possible that tumours
exert a local immune suppressive effect
in draining lymph nodes and this would
not be detected in our assays. Further-
more, it is also feasible that the dose of
thymus dependent antigens used was
sufficient to overcome any deficiency in
T cell function (Sinclair and Elliott,
1968; Taylor and Wortis, 1968). Finally,
it is also appreciated that the effect of
established tumours on humoral immune
response may be dependent upon the
type of tumour, its location and its
host.
The authors wish to thank Professor
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advice and encouragement, and J. Merri-
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